Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment

Purpose Vismodegib is a Hedgehog pathway inhibitor approved for the treatment of advanced basal cell carcinoma. Currently, the pharmacokinetics (PK) and safety of vismodegib in patients with hepatic dysfunction are unknown and are the objective of this study. Methods Patients with advanced solid mal...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology 2017-07, Vol.80 (1), p.29-36
Hauptverfasser:	Abou-Alfa, Ghassan K., Lewis, Lionel D., LoRusso, Patricia, Maitland, Michael, Chandra, Priya, Cheeti, Sravanthi, Colburn, Dawn, Williams, Sarah, Simmons, Brian, Graham, Richard A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Anilides - administration & dosage Anilides - adverse effects Anilides - pharmacokinetics Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Area Under Curve Basal cell carcinoma Bilirubin Cancer Research Cirrhosis Cohort Studies Disease Progression Dose-Response Relationship, Drug Fatalities Female Hepatocellular carcinoma Humans Hyperbilirubinemia Impairment Inhibitors Liver cancer Liver cirrhosis Liver Diseases - physiopathology Male Medicine Medicine & Public Health Middle Aged Neoplasms - drug therapy Neoplasms - pathology Oncology Oral cavity Original Article Patients Pharmacokinetics Pharmacology Pharmacology/Toxicology Population studies Pyridines - administration & dosage Pyridines - adverse effects Pyridines - pharmacokinetics Rendering Safety Severity of Illness Index Skin cancer Steady state Therapy Time Factors Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!